GT201000099A - Productos quimioterapéuticos cristalinos - Google Patents
Productos quimioterapéuticos cristalinosInfo
- Publication number
- GT201000099A GT201000099A GT201000099A GT201000099A GT201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A GT 201000099 A GT201000099 A GT 201000099A
- Authority
- GT
- Guatemala
- Prior art keywords
- crystal
- chemotherapeutic products
- chemotherapeutic
- products
- methylpenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A LA FORMA CRISTALINA 2 DE N-[4-(3-AMINO-1H-INDAZOL-4-IL) FENIL]-N´- (2-FLUORO -5-METILFENIL)UREA(ABT-869) QUE PERTENECE A UNA FAMILIA DE PROTEÍNA TIROSINA QUINASA (PTK) QUE CATALIZAN LA FOSFORILACIÓN DE RESIDUOS ESPECÍFICOS DE TIROSINA EN PROTEÍNAS POR LO QUE SON DE UTILIDAD EN TRASTORNOS O ENFERMEDADES PROLIFERATIVAS MALIGNAS RESULTANTES DE LA ACTIVACIÓN INAPROPIADA DEL SISTEMA INMUNE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98126507P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201000099A true GT201000099A (es) | 2012-03-26 |
Family
ID=40174735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201000099A GT201000099A (es) | 2007-10-19 | 2010-04-16 | Productos quimioterapéuticos cristalinos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7772404B2 (es) |
| EP (1) | EP2195299A1 (es) |
| JP (1) | JP2011500708A (es) |
| KR (1) | KR20100084665A (es) |
| CN (1) | CN101827825B (es) |
| AU (1) | AU2008312534A1 (es) |
| BR (1) | BRPI0818337A2 (es) |
| CA (1) | CA2699356A1 (es) |
| CO (1) | CO6270221A2 (es) |
| CR (1) | CR11444A (es) |
| DO (1) | DOP2010000111A (es) |
| EC (1) | ECSP10010175A (es) |
| GT (1) | GT201000099A (es) |
| MX (1) | MX2010004287A (es) |
| PA (1) | PA8800401A1 (es) |
| RU (1) | RU2010119920A (es) |
| UA (1) | UA99490C2 (es) |
| WO (1) | WO2009052231A1 (es) |
| ZA (1) | ZA201002094B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| WO2016022750A1 (en) | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2346538T3 (es) * | 2003-05-22 | 2010-10-18 | Abbott Laboratories | Inhibidores de quinasa de tipo indazol, benzisoxazol y benzisotiazol. |
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| EP1925676A4 (en) * | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| EP1962803A1 (en) * | 2005-12-23 | 2008-09-03 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| AU2007316558A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-15 US US12/251,918 patent/US7772404B2/en not_active Expired - Fee Related
- 2008-10-16 EP EP08839994A patent/EP2195299A1/en not_active Withdrawn
- 2008-10-16 CN CN2008801119519A patent/CN101827825B/zh not_active Expired - Fee Related
- 2008-10-16 KR KR1020107011003A patent/KR20100084665A/ko not_active Application Discontinuation
- 2008-10-16 RU RU2010119920/04A patent/RU2010119920A/ru not_active Application Discontinuation
- 2008-10-16 AU AU2008312534A patent/AU2008312534A1/en not_active Abandoned
- 2008-10-16 WO PCT/US2008/080068 patent/WO2009052231A1/en active Application Filing
- 2008-10-16 BR BRPI0818337A patent/BRPI0818337A2/pt not_active IP Right Cessation
- 2008-10-16 JP JP2010530094A patent/JP2011500708A/ja active Pending
- 2008-10-16 MX MX2010004287A patent/MX2010004287A/es active IP Right Grant
- 2008-10-16 CA CA2699356A patent/CA2699356A1/en not_active Abandoned
- 2008-10-16 UA UAA201006031A patent/UA99490C2/ru unknown
- 2008-10-17 PA PA20088800401A patent/PA8800401A1/es unknown
-
2010
- 2010-03-24 ZA ZA2010/02094A patent/ZA201002094B/en unknown
- 2010-04-16 DO DO2010000111A patent/DOP2010000111A/es unknown
- 2010-04-16 GT GT201000099A patent/GT201000099A/es unknown
- 2010-04-27 CO CO10049269A patent/CO6270221A2/es not_active Application Discontinuation
- 2010-05-14 EC EC2010010175A patent/ECSP10010175A/es unknown
- 2010-05-19 CR CR11444A patent/CR11444A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201002094B (en) | 2011-11-30 |
| BRPI0818337A2 (pt) | 2017-05-23 |
| ECSP10010175A (es) | 2010-06-29 |
| CN101827825A (zh) | 2010-09-08 |
| WO2009052231A1 (en) | 2009-04-23 |
| US7772404B2 (en) | 2010-08-10 |
| CA2699356A1 (en) | 2009-04-23 |
| JP2011500708A (ja) | 2011-01-06 |
| CR11444A (es) | 2010-10-05 |
| CN101827825B (zh) | 2012-11-21 |
| UA99490C2 (en) | 2012-08-27 |
| CO6270221A2 (es) | 2011-04-20 |
| AU2008312534A1 (en) | 2009-04-23 |
| DOP2010000111A (es) | 2010-07-15 |
| PA8800401A1 (es) | 2009-05-15 |
| MX2010004287A (es) | 2010-04-30 |
| RU2010119920A (ru) | 2011-11-27 |
| EP2195299A1 (en) | 2010-06-16 |
| US20090124816A1 (en) | 2009-05-14 |
| KR20100084665A (ko) | 2010-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121572T1 (el) | Σκευασμα δισκιου του ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου για χρηση στη θεραπεια κυστικης ινωσης | |
| NO20085243L (no) | Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting | |
| CY1109084T1 (el) | Προϊον ζαχαροπλαστικης με χαμηλα λιπαρα | |
| BR112014027244A2 (pt) | derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1 | |
| BRPI0607633A2 (pt) | mistura de oligossacarìdeo | |
| BR112014028841A2 (pt) | processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| BR122021002201A8 (pt) | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença | |
| EA201270225A1 (ru) | СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА | |
| BRPI0509903A (pt) | uso de compostos peptìdicos para profilaxia e tratamento da cefaléia crÈnica | |
| EA201270361A1 (ru) | Птеридины и их применение в качестве агрохимикатов | |
| GT201000099A (es) | Productos quimioterapéuticos cristalinos | |
| AR065278A1 (es) | Sales de derivado de benzotiazol | |
| GT201000101A (es) | Productos quimioterapéuticos cristalinos | |
| BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
| RS54639B1 (en) | PCSK9 VACCINE | |
| MA32717B1 (fr) | Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide | |
| CY1114618T1 (el) | Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη | |
| IL189286A0 (en) | Novel cysteine protease inhibitors and their therapeutic applications | |
| ATE472316T1 (de) | Haarbehandlungszusammensetzungen | |
| CY1112285T1 (el) | Υγρες φαρμακοτεχνικες μορφες αλατων 4-[2-(4-μεθυλφαινυλσουλφανυλ)φαινυλ]πιπεριδινης | |
| GT200600141A (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares | |
| DOP2010000112A (es) | Productos quimioterapeuticos cristalinos | |
| EA200702318A1 (ru) | Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
| GT201000093A (es) | Productos quimioterapéuticos cristalinos |